Peter A Calabresi

List of Publications by Year
in descending order

356 papers	28,096 citations	10070 75 h-index	8212 153 g-index
371 all docs	371 docs citations	371 times ranked	25038 citing authors

#	Article	IF	Citations
1	Optic Neuritisâ€“Independent Retinal Atrophy in Neuromyelitis Optica Spectrum Disorder. Journal of Neuro-Ophthalmology, 2022, 42, e40-e47.	0.4	5
2	OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103525.	0.9	36
3	Cerebellar Contributions to Motor and Cognitive Control in Multiple Sclerosisâœ°âœ°âœ°. Archives of Physical Medicine and Rehabilitation, 2022, 103, 1592-1599.	0.5	14
4	Type of serum collection tube does not impact neurofilament light chain levels. Multiple Sclerosis and Related Disorders, 2022, 59, 103676.	0.9	2
5	Multisite MRI reproducibility of lateral ventricular volume using the NAIMS cooperative pilot dataset. Journal of Neuroimaging, 2022, 32, 910-919.	1.0	2
6	Response toâ€”Tracking the role of sphingolipids in MS: The dynamic nature of ceramide synthases. Multiple Sclerosis Journal, 2022, , 135245852210840.	1.4	0
7	Breaking the barriers to remyelination in multiple sclerosis. Current Opinion in Pharmacology, 2022, 63, 102194.	1.7	6
8	Retinal pathology in spontaneous opticospinal experimental autoimmune encephalitis mice. Journal of Neuroimmunology, 2022, 367, 577859.	1.1	2
9	Reply to â€œInterpretation of Longitudinal Changes of the Inner Nuclear Layer in <scp>MS</scp>â€. Annals of Neurology, 2022, 92, 156-157.	2.8	0
10	Reactive Astrocytes Derived From Human Induced Pluripotent Stem Cells Suppress Oligodendrocyte Precursor Cell Differentiation. Frontiers in Molecular Neuroscience, 2022, 15, .	1.4	6
11	Proteomic Alterations and Novel Markers of Neurotoxic Reactive Astrocytes in Human Induced Pluripotent Stem Cell Models. Frontiers in Molecular Neuroscience, 2022, 15, 870085.	1.4	15
12	018â€… Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A19.1-A19.	0.9	0
13	Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis. Neurology, 2022, 99, .	1.5	7
14	Longitudinal Retinal Changes in <scp>MOGAD</scp>. Annals of Neurology, 2022, 92, 476-485.	2.8	20
15	The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis. Neurology, 2022, 99, .	1.5	21
16	From the prodromal stage of multiple sclerosis to disease prevention. Nature Reviews Neurology, 2022, 18, 559-572.	4.9	23
17	Mitochondrial measures in neuronally enriched extracellular vesicles predict brain and retinal atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2020-2026.	1.4	4
18	Contribution of B cells to cortical damage in multiple sclerosis. Brain, 2022, 145, 3363-3373.	3.7	15

#	Article	IF	Citations
19	Contributors to Serum <scp>NfL</scp> Levels in People without Neurologic Disease. Annals of Neurology, 2022, 92, 688-698.	2.8	25
20	Intermittent calorie restriction alters T cell subsets and metabolic markers in people with multiple sclerosis. EBioMedicine, 2022, 82, 104124.	2.7	29
21	Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring. Multiple Sclerosis Journal, 2021, 27, 1497-1505.	1.4	23
22	Serum ceramide levels are altered in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1506-1519.	1.4	20
23	Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD. Multiple Sclerosis Journal, 2021, 27, 1738-1748.	1.4	19
24	Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 549-558.	1.4	6
25	Synaptic and complement markers in extracellular vesicles in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 509-518.	1.4	38
26	Structured layer surface segmentation for retina OCT using fully convolutional regression networks. Medical Image Analysis, 2021, 68, 101856.	7.0	51
27	Reply to â€œRetinal <scp>INL</scp> Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration?â€• Annals of Neurology, 2021, 89, 193-194.	2.8	2
28	Single-cell transcriptomic reveals molecular diversity and developmental heterogeneity of human stem cell-derived oligodendrocyte lineage cells. Nature Communications, 2021, 12, 652.	5.8	47
29	Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. NeuroImage: Clinical, 2021, 32, 102834.	1.4	23
30	Is Cerebrospinal Fluid Responsible for Innate Immune Cell Activation and Neurotoxicity in Multiple Sclerosis?. Neurology, 2021, 96, 649-650.	1.5	4
31	Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis. Neurology, 2021, 96, e2058-e2069.	1.5	35
32	Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition. Brain, 2021, 144, 1396-1408.	3.7	44
33	Diversity and Function of Glial Cell Types in Multiple Sclerosis. Trends in Immunology, 2021, 42, 228-247.	2.9	41
34	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. Neurology, 2021, 97, 68-79.	1.5	96
35	Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis. Neurology, 2021, 96, e2525-e2533.	1.5	9
36	Artificial intelligence extension of the OSCARâ€IB criteria. Annals of Clinical and Translational Neurology, 2021, 8, 1528-1542.	1.7	33

#	Article	IF	Citations
37	Improving the efficacy of exome sequencing at a quaternary care referral centre: novel mutations, clinical presentations and diagnostic challenges in rare neurogenetic diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1186-1196.	0.9	9
38	Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis. Neurotherapeutics, 2021, 18, 1834-1848.	2.1	11
39	Complement component 3 from astrocytes mediates retinal ganglion cell loss during neuroinflammation. Acta Neuropathologica, 2021, 142, 899-915.	3.9	39
40	Trials and tribulations on the path to remyelination. Lancet Neurology, The, 2021, 20, 686-687.	4.9	1
41	A lymphocyteâ€“microgliaâ€“astrocyte axis in chronic active multiple sclerosis. Nature, 2021, 597, 709-714.	13.7	307
42	Information-Based Disentangled Representation Learning for Unsupervised MR Harmonization. Lecture Notes in Computer Science, 2021, , 346-359.	1.0	17
43	Socioeconomic disparity is associated with faster retinal neurodegeneration in multiple sclerosis. Brain, 2021, 144, 3664-3673.	3.7	13
44	Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism. Cell Reports Medicine, 2021, 2, 100424.	3.3	26
45	Measuring treatment response to advance precision medicine for multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 2166-2173.	1.7	6
46	Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine, 2021, 73, 103636.	2.7	85
47	Optical coherence tomography in multiple sclerosis: A 3â€year prospective multicenter study. Annals of Clinical and Translational Neurology, 2021, 8, 2235-2251.	1.7	36
48	Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 312-321.	1.4	27
49	Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures. Multiple Sclerosis Journal, 2020, 26, 815-828.	1.4	66
50	Monitoring diffuse injury during disease progression in experimental autoimmune encephalomyelitis with on resonance variable delay multiple pulse (onVDMP) CEST MRI. NeuroImage, 2020, 204, 116245.	2.1	10
51	Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Multiple Sclerosis Journal, 2020, 26, 1360-1371.	1.4	75
52	Immune cell modulation of oligodendrocyte lineage cells. Neuroscience Letters, 2020, 715, 134601.	1.0	32
53	Inhibition of neutral sphingomyelinase 2 promotes remyelination. Science Advances, 2020, 6, .	4.7	23
54	Combining Magnetization Transfer Ratio MRI and Quantitative Measures of Walking Improves the Identification of Fallers in MS. Brain Sciences, 2020, 10, 822.	1.1	2

#	Article	IF	Citations
55	Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. Annals of Neurology, 2020, 88, 1034-1042.	2.8	89
56	AQP4-IgG and MOG-IgG Related Optic Neuritisâ€"Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2020, 11, 540156.	1.1	66
57	Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy. Journal of Neuroimaging, 2020, 30, 251-266.	1.0	24
58	TAPAS: A Thresholding Approach for Probability Map Automatic Segmentation in Multiple Sclerosis. NeuroImage: Clinical, 2020, 27, 102256.	1.4	5
59	Evaluating White Matter Lesion Segmentations with Refined SÃ¸rensen-Dice Analysis. Scientific Reports, 2020, 10, 8242.	1.6	94
60	iPSCs from people with MS can differentiate into oligodendrocytes in a homeostatic but not an inflammatory milieu. PLoS ONE, 2020, 15, e0233980.	1.1	28
61	Socioeconomic status and race are correlated with affective symptoms in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 41, 102010.	0.9	32
62	Diffusionâ€time dependence of diffusional kurtosis in the mouse brain. Magnetic Resonance in Medicine, 2020, 84, 1564-1578.	1.9	22
63	Retinal pathology occurs in stiff-person syndrome. Neurology, 2020, 94, e2126-e2131.	1.5	5
64	Progressive Multiple Sclerosis Is Associated with Faster and Specific Retinal Layer Atrophy. Annals of Neurology, 2020, 87, 885-896.	2.8	56
65	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. Brain, 2020, 143, 1127-1142.	3.7	29
66	Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 843-854.	1.4	21
67	A Disentangled Latent Space for Cross-Site MRI Harmonization. Lecture Notes in Computer Science, 2020, , 720-729.	1.0	22
68	Variational intensity cross channel encoder for unsupervised vessel segmentation on OCT angiography. , 2020, , .		7
69	Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. Journal of Clinical Investigation, 2020, 130, 3467-3482.	3.9	109
70	Optical Coherence Tomography and Optical Coherence Tomography Angiography Findings After Optic Neuritis in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 618879.	1.1	17
71	Remyelination alters the pattern of myelin in the cerebral cortex. ELife, 2020, 9, .	2.8	67
72	Projection Artifact Suppression For Inner Retina In Oct Angiography. , 2019, , .		5

#	Article	IF	Citations
73	Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications, 2019, 7, 125.	2.4	47
74	Early complement genes are associated with visual system degeneration in multiple sclerosis. Brain, 2019, 142, 2722-2736.	3.7	30
75	DeepHarmony: A deep learning approach to contrast harmonization across scanner changes. Magnetic Resonance Imaging, 2019, 64, 160-170.	1.0	150
76	Applications of a deep learning method for anti-aliasing and super-resolution in MRI. Magnetic Resonance Imaging, 2019, 64, 132-141.	1.0	63
77	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 845-856.	4.9	110
78	Quetiapine has an additive effect to triiodothyronine in inducing differentiation of oligodendrocyte precursor cells through induction of cholesterol biosynthesis. PLoS ONE, 2019, 14, e0221747.	1.1	11
79	Glutamine antagonism attenuates physical and cognitive deficits in a model of MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	12
80	Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination. Nature Communications, 2019, 10, 3887.	5.8	245
81	NLRX1 inhibits the early stages of CNS inflammation and prevents the onset of spontaneous autoimmunity. PLoS Biology, 2019, 17, e3000451.	2.6	21
82	Multisite reliability and repeatability of an advanced brain MRI protocol. Journal of Magnetic Resonance Imaging, 2019, 50, 878-888.	1.9	27
83	Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes. Annals of Clinical and Translational Neurology, 2019, 6, 33-45.	1.7	39
84	Retinal layer parcellation of optical coherence tomography images: Data resource for multiple sclerosis and healthy controls. Data in Brief, 2019, 22, 601-604.	0.5	43
85	Longitudinal assessment of hand function in individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 32, 107-113.	0.9	19
86	Retinal measurements predict 10â€year disability in multiple sclerosis. Annals of Clinical and Translational Neurology, 2019, 6, 222-232.	1.7	50
87	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. Annals of Neurology, 2019, 85, 618-629.	2.8	104
88	Quantitative vibratory sensation measurement is related to sensory cortical thickness in <scp>MS</scp>. Annals of Clinical and Translational Neurology, 2019, 6, 586-595.	1.7	5
89	Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. Multiple Sclerosis and Related Disorders, 2019, 30, 136-140.	0.9	45
90	Imaging outcome measures of neuroprotection and repair in MS. Neurology, 2019, 92, 519-533.	1.5	53

#	Article	IF	Citations
91	Anti-CD20 therapy depletes activated myelin-specific CD8⁺T cells in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25800-25807.	3.3	71
92	Macular Ganglion Cell and Inner Plexiform Layer Thickness Is More Strongly Associated With Visual Function in Multiple Sclerosis Than Bruch Membrane Openingâ€"Minimum Rim Width or Peripapillary Retinal Nerve Fiber Layer Thicknesses. Journal of Neuro-Ophthalmology, 2019, 39, 444-450.	0.4	16
93	Aluinsertion variants alter mRNA splicing. Nucleic Acids Research, 2019, 47, 421-431.	6.5	58
94	Image Artifacts in Optical Coherence Tomography Angiography Among Patients With Multiple Sclerosis. Current Eye Research, 2019, 44, 558-563.	0.7	14
95	PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1686-1691.	3.3	140
96	Human iPSC-derived blood-brain barrier microvessels: validation of barrier function and endothelial cell behavior. Biomaterials, 2019, 190-191, 24-37.	5.7	141
97	Spinal cord and infratentorial lesions in radiologically isolated syndrome are associated with decreased retinal ganglion cell/inner plexiform layer thickness. Multiple Sclerosis Journal, 2019, 25, 1878-1887.	1.4	12
98	Characteristics of morphologic macular abnormalities in neuroimmunology practice. Multiple Sclerosis Journal, 2019, 25, 361-371.	1.4	2
99	Fully Convolutional Boundary Regression for Retina OCT Segmentation. Lecture Notes in Computer Science, 2019, 11764, 120-128.	1.0	44
100	Layer boundary evolution method for macular OCT layer segmentation. Biomedical Optics Express, 2019, 10, 1064.	1.5	24
101	Deep learning based topology guaranteed surface and MME segmentation of multiple sclerosis subjects from retinal OCT. Biomedical Optics Express, 2019, 10, 5042.	1.5	44
102	Central vein sign in multiple sclerosis. Neurology, 2018, 90, 631-632.	1.5	9
103	An Automated Statistical Technique for Counting Distinct Multiple Sclerosis Lesions. American Journal of Neuroradiology, 2018, 39, 626-633.	1.2	24
104	Visual Pathway Measures are Associated with Neuropsychological Function in Multiple Sclerosis. Current Eye Research, 2018, 43, 941-948.	0.7	15
105	Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis. Journal of Neuro-Ophthalmology, 2018, 38, 451-458.	0.4	46
106	Bryostatin-1 alleviates experimental multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2186-2191.	3.3	40
107	Defining response profiles after alemtuzumab. Neurology, 2018, 90, 309-311.	1.5	15
108	Analysis of Agreement of Retinal-Layer Thickness Measures Derived from the Segmentation of Horizontal and Vertical Spectralis OCT Macular Scans. Current Eye Research, 2018, 43, 415-423.	0.7	12

#	Article	IF	Citations
109	Multiple Sclerosis. New England Journal of Medicine, 2018, 378, 169-180.	13.9	1,653
110	Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science, 2018, 360, 449-453.	6.0	489
111	MIMoSA: An Automated Method for Intermodal Segmentation Analysis of Multiple Sclerosis Brain Lesions. Journal of Neuroimaging, 2018, 28, 389-398.	1.0	44
112	Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T₁â€weighted brain MRI acquisitions. Magnetic Resonance in Medicine, 2018, 79, 1595-1601.	1.9	27
113	Intensity inhomogeneity correction of SD-OCT data using macular flatspace. Medical Image Analysis, 2018, 43, 85-97.	7.0	4
114	Distinguishing among multiple sclerosis fallers, near-fallers and non-fallers. Multiple Sclerosis and Related Disorders, 2018, 19, 99-104.	0.9	21
115	Advances in multiple sclerosis: from reduced relapses to remedies. Lancet Neurology, The, 2018, 17, 10-12.	4.9	1
116	Dimethyl fumarate treatment alters NK cell function in multiple sclerosis. European Journal of Immunology, 2018, 48, 380-383.	1.6	41
117	The NAIMS cooperative pilot project: Design, implementation and future directions. Multiple Sclerosis Journal, 2018, 24, 1770-1772.	1.4	12
118	The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis. Journal of Neuro-Ophthalmology, 2018, 38, 494-501.	0.4	15
119	Microvascular blood flow velocities measured with a retinal function imager: inter-eye correlations in healthy controls and an exploration in multiple sclerosis. Eye and Vision (London, England), 2018, 5, 29.	1.4	13
120	Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study. Brain, 2018, 141, 3115-3129.	3.7	67
121	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	13.5	115
122	Deep Harmonization of Inconsistent MR Data for Consistent Volume Segmentation. Lecture Notes in Computer Science, 2018, , 20-30.	1.0	7
123	Emerging Applications of Optical Coherence Tomography Angiography (OCTA) in neurological research. Eye and Vision (London, England), 2018, 5, 11.	1.4	69
124	Multi-layer fast level set segmentation for macular OCT. , 2018, 2018, 1445-1448.		8
125	Dice Overlap Measures for Objects of Unknown Number: Application to Lesion Segmentation. Lecture Notes in Computer Science, 2018, 10670, 3-14.	1.0	5
126	Joint Intensity Fusion Image Synthesis Applied to Multiple Sclerosis Lesion Segmentation. Lecture Notes in Computer Science, 2018, , 43-54.	1.0	3

#	Article	IF	Citations
127	Joint Intensity Fusion Image Synthesis Applied to Multiple Sclerosis Lesion Segmentation. , 2018, 10670, 43-54.		2
128	Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions?. Multiple Sclerosis Journal, 2017, 23, 43-50.	1.4	40
129	Optical coherence tomography: A quantitative tool to measure neurodegeneration and facilitate testing of novel treatments for tissue protection in multiple sclerosis. Journal of Neuroimmunology, 2017, 304, 93-96.	1.1	17
130	Disease-modifying therapies modulate retinal atrophy in multiple sclerosis. Neurology, 2017, 88, 525-532.	1.5	73
131	Longitudinal multiple sclerosis lesion segmentation: Resource and challenge. NeuroImage, 2017, 148, 77-102.	2.1	215
132	Retinal Architecture and Melanopsin-Mediated Pupillary Response Characteristics. JAMA Neurology, 2017, 74, 574.	4.5	27
133	Neuropsychiatric syndromes of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 697-708.	0.9	97
134	Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology â€“ Commentary. Multiple Sclerosis Journal, 2017, 23, 376-377.	1.4	1
135	Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial. BMC Neurology, 2017, 17, 29.	0.8	24
136	Longitudinal multiple sclerosis lesion segmentation data resource. Data in Brief, 2017, 12, 346-350.	0.5	31
137	Dimethyl fumarate alters Bâ€cell memory and cytokine production in MS patients. Annals of Clinical and Translational Neurology, 2017, 4, 351-355.	1.7	54
138	Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series. Multiple Sclerosis Journal, 2017, 23, 1035-1039.	1.4	23
139	Quantitative measures of walking and strength provide insight into brain corticospinal tract pathology in multiple sclerosis. NeuroImage: Clinical, 2017, 14, 490-498.	1.4	37
140	CNS-targeted autoimmunity leads to increased influenza mortality in mice. Journal of Experimental Medicine, 2017, 214, 297-307.	4.2	16
141	B-Cell Depletion â€” A Frontier in Monoclonal Antibodies for Multiple Sclerosis. New England Journal of Medicine, 2017, 376, 280-282.	13.9	26
142	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurology, The, 2017, 16, 797-812.	4.9	397
143	Towards Topological Correct Segmentation ofÂMacular OCT from Cascaded FCNs. Lecture Notes in Computer Science, 2017, 10554, 202-209.	1.0	31
144	Lineage tracing reveals dynamic changes in oligodendrocyte precursor cells following cuprizoneâ€induced demyelination. Glia, 2017, 65, 2087-2098.	2.5	81

#	Article	IF	Citations
145	Volumetric Analysis from a Harmonized Multisite Brain MRI Study of a Single Subject with Multiple Sclerosis. American Journal of Neuroradiology, 2017, 38, 1501-1509.	1.2	95
146	Thalamus segmentation using multi-modal feature classification: Validation and pilot study of an age-matched cohort. NeuroImage, 2017, 158, 430-440.	2.1	20
147	Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis. Clinical Pharmacology and Therapeutics, 2017, 101, 52-64.	2.3	12
148	The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard â€˜Dickâ€™ T. Johnson. Journal of Neurology, 2017, 264, 817-828.	1.8	1
149	Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. JCI Insight, 2017, 2, .	2.3	79
150	Magnetic susceptibility contrast variations in multiple sclerosis lesions. Journal of Magnetic Resonance Imaging, 2016, 43, 463-473.	1.9	79
151	Simultaneous segmentation of retinal surfaces and microcystic macular edema in SDOCT volumes. Proceedings of SPIE, 2016, 9784, .	0.8	11
152	Combined registration and motion correction of longitudinal retinal OCT data. Proceedings of SPIE, 2016, 9784, .	0.8	13
153	Thalamus parcellation using multi-modal feature classification and thalamic nuclei priors. , 2016, 9784, .		6
154	Voxel based morphometry in optical coherence tomography: validation and core findings. , 2016, 9788, .		8
155	Increased TNFR1 expression and signaling in injured peripheral nerves of mice with reduced BACE1 activity. Neurobiology of Disease, 2016, 93, 21-27.	2.1	9
156	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology, 2016, 87, 1424-1424.	1.5	0
157	Intensity inhomogeneity correction of macular OCT using N3 and retinal flatspace. , 2016, 2016, 197-200.		5
158	How global MS prevalence is changing: A retrospective chart review in the United Arab Emirates. Multiple Sclerosis and Related Disorders, 2016, 9, 73-79.	0.9	32
159	Multiple Sclerosis. Seminars in Neurology, 2016, 36, 350-356.	0.5	13
160	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology, 2016, 87, 446-446.	1.5	0
161	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology, 2016, 87, 445-446.	1.5	0
162	Pain, cognition and quality of life associate with structural measures of brain volume loss in multiple sclerosis. NeuroRehabilitation, 2016, 39, 535-544.	0.5	13

#	Article	IF	Citations
163	Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis. Journal of Visualized Experiments, 2016, , e53449.	0.2	8
164	20/40 or Better Visual Acuity After Optic Neuritis: Not as Good as We Once Thought?. Journal of Neuro-Ophthalmology, 2016, 36, 369-376.	0.4	30
165	Preparation of Rat Oligodendrocyte Progenitor Cultures and Quantification of Oligodendrogenesis Using Dual-infrared Fluorescence Scanning. Journal of Visualized Experiments, 2016, , 53764.	0.2	7
166	Is my MS patient failing treatment?. Neurology, 2016, 87, 124-125.	1.5	1
167	Phenytoin in acute optic neuritis: neuroprotective or not?. Lancet Neurology, The, 2016, 15, 233-235.	4.9	9
168	Metabolomics in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 451-460.	1.4	49
169	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurology, The, 2016, 15, 574-584.	4.9	266
170	Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis Severity. American Journal of Neuroradiology, 2016, 37, 1447-1453.	1.2	73
171	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology, 2016, 86, 382-390.	1.5	124
172	Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Multiple Sclerosis Journal, 2016, 22, 302-311.	1.4	106
173	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clinical Cancer Research, 2016, 22, 1161-1172.	3.2	57
174	OCT in Relapsingâ€“Remitting Multiple Sclerosis (RRMS). , 2016, , 113-133.		0
175	Outer retinal changes following acute optic neuritis. Multiple Sclerosis Journal, 2016, 22, 362-372.	1.4	53
176	Optical coherence tomography reflects brain atrophy in multiple sclerosis: A fourâ€year study. Annals of Neurology, 2015, 78, 801-813.	2.8	304
177	Basic principles of optical coherence tomography. , 2015, , 4-13.		2
178	Applying an Open-Source Segmentation Algorithm to Different OCT Devices in Multiple Sclerosis Patients and Healthy Controls: Implications for Clinical Trials. Multiple Sclerosis International, 2015, 2015, 1-10.	0.4	35
179	Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. Journal of the Neurological Sciences, 2015, 355, 59-63.	0.3	68
180	Longitudinal relationships among posturography and gait measures in multiple sclerosis. Neurology, 2015, 84, 2048-2056.	1.5	32

#	Article	IF	Citations
181	Segmentation of microcystic macular edema in Cirrus OCT scans with an exploratory longitudinal study. Proceedings of SPIE, 2015, 9417, .	0.8	7
182	Relationships between quantitative spinal cord MRI and retinal layers in multiple sclerosis. Neurology, 2015, 84, 720-728.	1.5	52
183	Novel therapies for memory cells in autoimmune diseases. Clinical and Experimental Immunology, 2015, 180, 353-360.	1.1	22
184	Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology. Multiple Sclerosis Journal, 2015, 21, 1139-1150.	1.4	49
185	1,25-Dihydroxyvitamin D3 impairs the differentiation of effector memory T cells in vitro in multiple sclerosis patients and healthy controls. Journal of Neuroimmunology, 2015, 279, 20-24.	1.1	9
186	Longitudinal graph-based segmentation of macular OCT using fundus alignment. Proceedings of SPIE, 2015, 9413, .	0.8	8
187	Transfer of Myelin-Reactive Th17 Cells Impairs Endogenous Remyelination in the Central Nervous System of Cuprizone-Fed Mice. Journal of Neuroscience, 2015, 35, 8626-8639.	1.7	86
188	Antigenic Stimulation of Kv1.3-Deficient Th Cells Gives Rise to a Population of Foxp3-Independent T Cells with Suppressive Properties. Journal of Immunology, 2015, 195, 1399-1407.	0.4	10
189	Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis. JAMA Neurology, 2015, 72, 1004.	4.5	140
190	Targeting Repulsive Guidance Molecule A to Promote Regeneration and Neuroprotection in Multiple Sclerosis. Cell Reports, 2015, 10, 1887-1898.	2.9	62
191	The Impact of Dynamic Balance Measures on Walking Performance in Multiple Sclerosis. Neurorehabilitation and Neural Repair, 2015, 29, 62-69.	1.4	41
192	Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology, 2015, 85, 18-28.	1.5	247
193	Retinal damage and vision loss in <scp>A</scp>frican <scp>A</scp>merican multiple sclerosis patients. Annals of Neurology, 2015, 77, 228-236.	2.8	53
194	Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Multiple Sclerosis Journal, 2015, 21, 163-170.	1.4	237
195	Automatic segmentation of microcystic macular edema in OCT. Biomedical Optics Express, 2015, 6, 155.	1.5	60
196	Multiple-object geometric deformable model for segmentation of macular OCT: errata. Biomedical Optics Express, 2015, 6, 1351.	1.5	0
197	Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica. Acta Neuropathologica Communications, 2015, 3, 28.	2.4	44
198	Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 304-310.	0.9	18

#	Article	IF	Citations
199	Quantitative sensory and motor measures detect change over time and correlate with walking speed in individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 67-74.	0.9	32
200	Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Multiple Sclerosis Journal, 2015, 21, 1025-1035.	1.4	91
201	Hiding in plain sight: a closer look at posterior cortical atrophy. Practical Neurology, 2015, 15, 5-13.	0.5	34
202	A Comparison of Supervised Machine Learning Algorithms and Feature Vectors for MS Lesion Segmentation Using Multimodal Structural MRI. PLoS ONE, 2014, 9, e95753.	1.1	38
203	Health Effects of Lesion Localization in Multiple Sclerosis: Spatial Registration and Confounding Adjustment. PLoS ONE, 2014, 9, e107263.	1.1	19
204	Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology, 2014, 82, 984-988.	1.5	22
205	Complex antibody profiling to predict clinical outcome in childhood ADS. Neurology, 2014, 83, 2200-2201.	1.5	0
206	Retinal architecture and mfERG. Neurology, 2014, 82, 1888-1896.	1.5	12
207	Microcystic macular edema detection in retina OCT images. , 2014, , .		2
208	Multiple-object geometric deformable model for segmentation of macular OCT. Biomedical Optics Express, 2014, 5, 1062.	1.5	51
209	Analysis of macular OCT images using deformable registration. Biomedical Optics Express, 2014, 5, 2196.	1.5	28
210	Single-use autoinjector for peginterferon-Î²1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study. Expert Opinion on Drug Delivery, 2014, 11, 1713-1720.	2.4	12
211	Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain, 2014, 137, 2271-2286.	3.7	128
212	Reply: Photoreceptor layer thinning is not specific for Parkinson's disease. Movement Disorders, 2014, 29, 1332-1332.	2.2	0
213	Reconstruction of the human cerebral cortex robust to white matter lesions: Method and validation. Human Brain Mapping, 2014, 35, 3385-3401.	1.9	33
214	Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurology, 2014, 14, 240.	0.8	40
215	An adaptive grid for graph-based segmentation in retinal OCT. Proceedings of SPIE, 2014, 9034, .	0.8	13
216	Monocular and binocular low-contrast visual acuity and optical coherence tomography in pediatric multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 326-334.	0.9	41

#	Article	IF	Citations
217	Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurology, The, 2014, 13, 657-665.	4.9	339
218	Mesenchymal Stem Cells Differentially Modulate Effector CD8+ T Cell Subsets and Exacerbate Experimental Autoimmune Encephalomyelitis. Stem Cells, 2014, 32, 2744-2755.	1.4	51
219	Spinal Cord Normalization in Multiple Sclerosis. Journal of Neuroimaging, 2014, 24, 577-584.	1.0	35
220	Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Yes. Multiple Sclerosis Journal, 2014, 20, 1296-1298.	1.4	24
221	Statistical normalization techniques for magnetic resonance imaging. NeuroImage: Clinical, 2014, 6, 9-19.	1.4	300
222	A selective thyroid hormone Î² receptor agonist enhances human and rodent oligodendrocyte differentiation. Glia, 2014, 62, 1513-1529.	2.5	66
223	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.5	2,344
224	FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway. Journal of Neuroimmunology, 2014, 270, 13-21.	1.1	42
225	Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS) Tj ETQq1 1 0.784314 rgBT /Over 545-556.	4.9	707
226	Photoreceptor layer thinning in idiopathic Parkinson's disease. Movement Disorders, 2014, 29, 1163-1170.	2.2	84
227	Impaired toll-like receptor 8 signaling in multiple sclerosis. Journal of Neuroinflammation, 2013, 10, 74.	3.1	26
228	Axial 3D gradient-echo imaging for improved multiple sclerosis lesion detection in the cervical spinal cord at 3T. Neuroradiology, 2013, 55, 431-439.	1.1	35
229	Anti-interleukin-2 receptor alpha for multiple sclerosis?. Lancet, The, 2013, 381, 2141-2143.	6.3	1
230	Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2013, 70, 248.	4.5	13
231	Intensity standardization of longitudinal images using 4D clustering. , 2013, , .		1
232	1,25-Dihydroxyvitamin D ₃ selectively and reversibly impairs T helper-cell CNS localization. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 21101-21106.	3.3	50
233	Emerging injectable therapies for multiple sclerosis. Lancet Neurology, The, 2013, 12, 1115-1126.	4.9	31
234	Optical Coherence Tomography in X-Linked Adrenoleukodystrophy. Pediatric Neurology, 2013, 49, 182-184.	1.0	7

#	Article	IF	Citations
235	OASIS is Automated Statistical Inference for Segmentation, with applications to multiple sclerosis lesion segmentation in MRI. NeuroImage: Clinical, 2013, 2, 402-413.	1.4	80
236	Helper T cells down-regulate CD4 expression upon chronic stimulation giving rise to double-negative T cells. Cellular Immunology, 2013, 284, 68-74.	1.4	35
237	Accelerated axon loss in MOG35-55 experimental autoimmune encephalomyelitis (EAE) in myelin-associated glycoprotein-deficient (MAGKO) mice. Journal of Neuroimmunology, 2013, 262, 53-61.	1.1	13
238	Relationships Between Retinal Axonal and Neuronal Measures and Global Central Nervous System Pathology in Multiple Sclerosis. JAMA Neurology, 2013, 70, 34.	4.5	197
239	Voxel-wise displacement as independent features in classification of multiple sclerosis. , 2013, 8669, .		2
240	The expanding spectrum of aetiologies causing retinal microcystic macular change. Brain, 2013, 136, 3212-3214.	3.7	20
241	In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology, 2013, 80, 1406-1414.	1.5	138
242	Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain, 2013, 136, 2888-2903.	3.7	174
243	Optic nerve head component responses of the multifocal electroretinogram in MS. Neurology, 2013, 81, 545-551.	1.5	11
244	Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 427-435.	1.4	68
245	Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology, 2013, 80, 47-54.	1.5	200
246	A lipid storageâ€“like disorder contributes to cognitive decline in HIV-infected subjects. Neurology, 2013, 81, 1492-1499.	1.5	53
247	Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis. Neurology, 2013, 80, 540-547.	1.5	72
248	Baseline Retinal Nerve Fiber Layer Thickness and Macular Volume Quantified by OCT in the North American Phase 3 Fingolimod Trial for Relapsingâ€“Remitting Multiple Sclerosis. Journal of Neuro-Ophthalmology, 2013, 33, 322-329.	0.4	31
249	In Vivo Demonstration of Homonymous Hemimacular Loss of Retinal Ganglion Cells Due to a Thalamic Lesion Using Optical Coherence Tomography. JAMA Neurology, 2013, 70, 410.	4.5	5
250	Optical coherence tomography does not support optic nerve involvement in amyotrophic lateral sclerosis. European Journal of Neurology, 2013, 20, 1170-1176.	1.7	45
251	Comparison of Point Estimates and Average Thicknesses of Retinal Layers Measured Using Manual Optical Coherence Tomography Segmentation for Quantification of Retinal Neurodegeneration in Multiple Sclerosis. Current Eye Research, 2013, 38, 224-228.	0.7	13
252	Deformable registration of macular oct using a-mode scan similarity. , 2013, 2013, 476-479.		11

#	Article	IF	Citations
253	Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13588-13593.	3.3	218
254	Retinal layer segmentation of macular OCT images using boundary classification. Biomedical Optics Express, 2013, 4, 1133.	1.5	265
255	KLF4 Modulates Expression of IL-6 in Dendritic Cells via Both Promoter Activation and Epigenetic Modification. Journal of Biological Chemistry, 2013, 288, 23868-23874.	1.6	56
256	Clay-shovelerâ€™s Fracture During Indoor Rock Climbing. Orthopedics, 2013, 36, e381-3.	0.5	15
257	Blockade of Kv1.3 Potassium Channels Inhibits Differentiation and Granzyme B Secretion of Human CD8+ T Effector Memory Lymphocytes. PLoS ONE, 2013, 8, e54267.	1.1	25
258	Kv1.3 Deletion Biases T Cells toward an Immunoregulatory Phenotype and Renders Mice Resistant to Autoimmune Encephalomyelitis. Journal of Immunology, 2012, 188, 5877-5886.	0.4	65
259	Visual Pathway Axonal Loss in Benign Multiple Sclerosis. Journal of Neuro-Ophthalmology, 2012, 32, 116-123.	0.4	35
260	Investigating Axonal Damage in Multiple Sclerosis by Diffusion Tensor Spectroscopy. Journal of Neuroscience, 2012, 32, 6665-6669.	1.7	63
261	Inhibition of Glutamate Carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 20101-20106.	3.3	57
262	Functional Blockade of the Voltage-gated Potassium Channel Kv1.3 Mediates Reversion of T Effector to Central Memory Lymphocytes through SMAD3/p21cip1 Signaling*. Journal of Biological Chemistry, 2012, 287, 1261-1268.	1.6	28
263	Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology, 2012, 79, 2002-2004.	1.5	75
264	In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques. Journal of Neurology, 2012, 259, 2119-2130.	1.8	83
265	Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain, 2012, 135, 521-533.	3.7	306
266	Ganglion Cell Loss in Relation to Visual Disability in Multiple Sclerosis. Ophthalmology, 2012, 119, 1250-1257.	2.5	260
267	Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS. Neurology, 2012, 79, 797-801.	1.5	23
268	Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurology, The, 2012, 11, 963-972.	4.9	267
269	PEGylation of Interferon-Î²-1a. CNS Drugs, 2012, 26, 205-214.	2.7	56
270	Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. Journal of the Neurological Sciences, 2012, 318, 119-124.	0.3	52

#	Article	IF	Citations
271	Objective characterization of the relative afferent pupillary defect in MS. Journal of the Neurological Sciences, 2012, 323, 193-200.	0.3	13
272	Revisiting Brain Atrophy and Its Relationship to Disability in Multiple Sclerosis. PLoS ONE, 2012, 7, e37049.	1.1	97
273	Granzyme B-Induced Neurotoxicity Is Mediated via Activation of PAR-1 Receptor and Kv1.3 Channel. PLoS ONE, 2012, 7, e43950.	1.1	43
274	Detection of clinical and subclinical retinal abnormalities in neurosarcoidosis with optical coherence tomography. Journal of Neurology, 2012, 259, 1390-1398.	1.8	20
275	New and emerging disease modifying therapies for multiple sclerosis. Annals of the New York Academy of Sciences, 2012, 1247, 117-137.	1.8	42
276	ADVANCE Phase 3 Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis: Patient Baseline Characteristics (P01.133). Neurology, 2012, 78, P01.133-P01.133.	1.5	6
277	Diffusion Tensor and Magnetization Transfer Imaging Correlates of Motor Dysfunction in the Spinal Cord in Multiple Sclerosis (S21.002). Neurology, 2012, 78, S21.002-S21.002.	1.5	1
278	Quantitative measures detect sensory and motor impairments in multiple sclerosis. Journal of the Neurological Sciences, 2011, 305, 103-111.	0.3	56
279	Inflammation in Multiple Sclerosis â€" Sorting Out the Gray Matter. New England Journal of Medicine, 2011, 365, 2231-2233.	13.9	3
280	Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Multiple Sclerosis Journal, 2011, 17, 1449-1463.	1.4	239
281	One Eye or Two: A Comparison of Binocular and Monocular Low-Contrast Acuity Testing in Multiple Sclerosis. American Journal of Ophthalmology, 2011, 152, 133-140.	1.7	55
282	Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet, The, 2011, 378, 1779-1787.	6.3	636
283	The Impact of Utilizing Different Optical Coherence Tomography Devices for Clinical Purposes and in Multiple Sclerosis Trials. PLoS ONE, 2011, 6, e22947.	1.1	72
284	Optical Coherence Tomography (OCT): Imaging the Visual Pathway as a Model for Neurodegeneration. Neurotherapeutics, 2011, 8, 117-132.	2.1	145
285	Stratus OCT Quality Control in Two Multi-Centre Multiple Sclerosis Clinical Trials. Neuro-Ophthalmology, 2011, 35, 57-64.	0.4	10
286	Retinal Ganglion Cell Layer Volumetric Assessment by Spectral-Domain Optical Coherence Tomography in Multiple Sclerosis: Application of a High-Precision Manual Estimation Technique. Journal of Neuro-Ophthalmology, 2011, 31, 260-264.	0.4	57
287	Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain, 2011, 134, 518-533.	3.7	291
288	Complex geometric models of diffusion and relaxation in healthy and damaged white matter. NMR in Biomedicine, 2010, 23, 152-162.	1.6	29

#	Article	IF	Citations
289	Reproducibility of tractâ€specific magnetization transfer and diffusion tensor imaging in the cervical spinal cord at 3 tesla. NMR in Biomedicine, 2010, 23, 207-217.	1.6	59
290	Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurology, The, 2010, 9, 921-932.	4.9	503
291	FLT-3 expression and function on microglia in multiple sclerosis. Experimental and Molecular Pathology, 2010, 89, 109-116.	0.9	17
292	Abnormal Bâ€cell cytokine responses a trigger of Tâ€cellâ€“mediated disease in MS?. Annals of Neurology, 2010, 67, 452-461.	2.8	428
293	Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Annals of Neurology, 2010, 67, 749-760.	2.8	308
294	qâ€space and conventional diffusion imaging of axon and myelin damage in the rat spinal cord after axotomy. Magnetic Resonance in Medicine, 2010, 63, 1323-1335.	1.9	43
295	Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 829-839.	1.4	98
296	Activated T-Cells Inhibit Neurogenesis by Releasing Granzyme B: Rescue by Kv1.3 Blockers. Journal of Neuroscience, 2010, 30, 5020-5027.	1.7	50
297	Cutting Edge: The Transcription Factor Kruppel-Like Factor 4 Regulates the Differentiation of Th17 Cells Independently of RORÎ³t. Journal of Immunology, 2010, 185, 7161-7164.	0.4	45
298	Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology. Brain, 2010, 133, 1575-1577.	3.7	23
299	Can retinal imaging accurately detect optic neuritis?. Nature Reviews Neurology, 2010, 6, 125-126.	4.9	8
300	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the Neurological Sciences, 2010, 292, 28-35.	0.3	56
301	A topology-preserving approach to the segmentation of brain images with multiple sclerosis lesions. NeuroImage, 2010, 49, 1524-1535.	2.1	287
302	Automated vs. conventional tractography in multiple sclerosis: Variability and correlation with disability. NeuroImage, 2010, 49, 3047-3056.	2.1	43
303	Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nature Reviews Neurology, 2009, 5, 256-266.	4.9	352
304	Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain, 2009, 132, 1200-1209.	3.7	130
305	Signal Transduction Inhibition of APCs Diminishes Th17 and Th1 Responses in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2009, 182, 4192-4199.	0.4	48
306	Damage to the Optic Radiation in Multiple Sclerosis Is Associated With Retinal Injury and Visual Disability. Archives of Neurology, 2009, 66, 998-1006.	4.9	142

#	Article	IF	Citations
307	Axonal Protective Effects of the Myelin-Associated Glycoprotein. Journal of Neuroscience, 2009, 29, 630-637.	1.7	121
308	Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized doubleâ€blind placeboâ€controlled multicenter trial. Annals of Neurology, 2009, 66, 460-471.	2.8	815
309	Retinal architecture predicts pupillary reflex metrics in MS. Multiple Sclerosis Journal, 2009, 15, 479-486.	1.4	20
310	Diffusion Tensor Magnetic Resonance Imaging of Wallerian Degeneration in Rat Spinal Cord after Dorsal Root Axotomy. Journal of Neuroscience, 2009, 29, 3160-3171.	1.7	167
311	Macular Volume Determined by Optical Coherence Tomography as a Measure of Neuronal Loss in Multiple Sclerosis. Archives of Neurology, 2009, 66, 1366-72.	4.9	165
312	Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nature Clinical Practice Neurology, 2008, 4, 664-675.	2.7	282
313	Retinal Imaging by Laser Polarimetry and Optical Coherence Tomography Evidence of Axonal Degeneration in Multiple Sclerosis. Archives of Neurology, 2008, 65, 924-8.	4.9	114
314	A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain, 2008, 131, 3092-3102.	3.7	148
315	Reproducibility of Optical Coherence Tomography in Multiple Sclerosis. Archives of Neurology, 2008, 65, 1218-22.	4.9	72
316	Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis. Archives of Neurology, 2008, 65, 1044-51.	4.9	78
317	Investigating glatiramer acetate for relapsingâ€“remitting multiple sclerosis at the double doseâ€”is more better?. Nature Clinical Practice Neurology, 2007, 3, 540-541.	2.7	2
318	High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain, 2007, 130, 2199-2210.	3.7	183
319	Characterization of the Functional Properties of the Voltage-Gated Potassium Channel Kv1.3 in Human CD4+ T Lymphocytes. Journal of Immunology, 2007, 179, 4563-4570.	0.4	86
320	Multiparametric magnetic resonance imaging analysis of the corticospinal tract in multiple sclerosisâ˜†. NeuroImage, 2007, 38, 271-279.	2.1	84
321	Agar-gelatin for embedding tissues prior to paraffin processing. BioTechniques, 2007, 42, 569-570.	0.8	41
322	Healthâ€related quality of life in multiple sclerosis: effects of natalizumab. Annals of Neurology, 2007, 62, 335-346.	2.8	172
323	Dendritic cells are abundant in non-lesional gray matter in multiple sclerosis. Experimental and Molecular Pathology, 2007, 83, 198-206.	0.9	24
324	Relation of Visual Function to Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis. Ophthalmology, 2006, 113, 324-332.	2.5	589

#	Article	IF	Citations
325	Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Annals of Neurology, 2006, 60, 118-127.	2.8	55
326	Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17414-17419.	3.3	470
327	Granzyme B mediates neurotoxicity through a Gâ€proteinâ€coupled receptor. FASEB Journal, 2006, 20, 1209-1211.	0.2	56
328	IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. Journal of Clinical Investigation, 2005, 115, 2731-2741.	3.9	115
329	Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16741-16746.	3.3	96
330	Targeting Effector Memory T Cells with a Selective Peptide Inhibitor of Kv1.3 Channels for Therapy of Autoimmune Diseases. Molecular Pharmacology, 2005, 67, 1369-1381.	1.0	232
331	The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11094-11099.	3.3	172
332	Diagnosis and management of multiple sclerosis. American Family Physician, 2004, 70, 1935-44.	0.1	128
333	Kinetics of CCR7 expression differ between primary activation and effector memory states of TH1 and TH2 cells. Journal of Neuroimmunology, 2003, 139, 58-65.	1.1	11
334	The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. Journal of Clinical Investigation, 2003, 111, 1703-1713.	3.9	368
335	Chemokine receptor expression on MBP-reactive T cells: CXCR6 is a marker of IFNÎ³-producing effector cells. Journal of Neuroimmunology, 2002, 127, 96-105.	1.1	32
336	Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology, 2002, 58, S10-22.	1.5	54
337	Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Annals of Neurology, 1998, 43, 116-120.	2.8	73
338	Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon ?-1b. Annals of Neurology, 1997, 41, 669-674.	2.8	149
339	Optical coherence tomography pathologies to know about in clinical practice. , 0, , 145-155.		1
340	Optical coherence tomography and visual outcomes in acute optic neuritis. , 0, , 42-60.		0
341	Introduction to optical coherence tomography in neurological diseases. , 0, , 1-3.		0
342	Anatomy of the anterior visual pathway. , 0, , 14-27.		0

#	Article	IF	Citations
343	Optical coherence tomography in acute optic neuritis. , 0, , 28-41.		0
344	Optical coherence tomography and low-contrast acuity. , 0, , 61-75.		1
345	Optical coherence tomography and electrophysiology of the visual pathway. , 0, , 76-88.		0
346	Optical coherence tomography and electrophysiology of the optic nerve head. , 0, , 89-102.		0
347	Meta-analysis of optical coherence tomography in multiple sclerosis. , 0, , 103-113.		1
348	Optical coherence tomography and brain magnetic resonance imaging in multiple sclerosis. , 0, , 114-127.		0
349	Optical coherence tomography in neurodegenerative and other neurologic diseases. , 0, , 128-144.		0
350	Optical coherence tomography and retinal segmentation in neurological diseases. , 0, , 156-164.		1
351	Optical coherence tomography and retinal pathology in neurologic diseases. , 0, , 165-175.		0
352	Retinal inflammation in multiple sclerosis revealed by optical coherence tomography and ophthalmoscopy. , 0, , 176-183.		0
353	Optical coherence tomography and optic nerve magnetic resonance imaging in demyelinating diseases. , 0, , 184-190.		0
354	Optical coherence tomography in neurologic clinical trials. , 0, , 191-197.		0
355	Optical coherence tomography in a multi-center setting: quality control issues. , 0, , 198-208.		0
356	Future technological advances in optical coherence tomography. , 0, , 209-217.		0